Physician profile
Darcy E Scheeler
NPI 1740315316
$7,416.17
in general payments reported to CMS, 2019-2025
48 companies · $871 in 2025
The $871 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $1,114 · 2021: $972 · 2022: $1,421 · 2023: $1,247 · 2024: $962 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,685.16 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,005.82 | 2019-2025 | Repatha, Otezla, Evenity |
| Allergan, INC. | $627.41 | 2019-2021 | |
| Pfizer INC. | $533.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $424.68 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $370.32 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $271.06 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $260.69 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $236.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $159.66 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $145.96 | 2019-2024 | Airsupra |
| Eisai INC. | $121.13 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $120.29 | 2022-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.43 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $96.51 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darcy Scheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.